Gerresheimer AG (GRRMF)
- Previous Close
73.95 - YTD Return --
- Expense Ratio --
- Category --
- Last Cap Gain --
- Morningstar Rating --
- Morningstar Risk Rating --
- Sustainability Rating --
- Net Assets --
- Beta (5Y Monthly) --
- Yield --
- 5y Average Return --
- Holdings Turnover --
- Last Dividend --
- Inception Date --
People Also Watch
Recent News: GRRMF
View More
Research Reports: GRRMF
View MoreConvaTec's Turnaround Plan Gains Operational Strength
Originally spun out of Bristol-Myers Squibb, ConvaTec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 33% and 28% of total revenue, respectively. Continence care has become a slightly smaller business (21% of revenue) following the decision to exit the acute care market, and infusion sets contribute 18% of consolidated revenue.
RatingPrice TargetConvatec Earnings: Investment in Turnaround Paid Dividends in 2024
Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 33% and 29% of total revenue, respectively. Continence care has become a slightly smaller business (21% of revenue) following the decision to exit the acute care market, and infusion sets contribute 17% of consolidated revenue.
RatingPrice TargetConvatec Earnings: Abbreviated Results Underscore Accelerating Growth
Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 33% and 29% of total revenue, respectively. Continence care has become a slightly smaller business (21% of revenue) following the decision to exit the acute care market, and infusion sets contribute 17% of consolidated revenue.
RatingPrice TargetConvatec Earnings: Abbreviated Results Underscore Accelerating Growth
Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 33% and 29% of total revenue, respectively. Continence care has become a slightly smaller business (21% of revenue) following the decision to exit the acute care market, and infusion sets contribute 17% of consolidated revenue.
RatingPrice Target